Short Interest in MetaVia Inc. (NASDAQ:MTVA) Decreases By 69.4%

MetaVia Inc. (NASDAQ:MTVA) was the target of a large drop in short interest in December. As of December 15th, there was short interest totaling 60,602 shares, a drop of 69.4% from the November 30th total of 198,092 shares. Approximately 2.8% of the shares of the stock are sold short. Based on an average daily volume of 425,605 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 425,605 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.8% of the shares of the stock are sold short.

MetaVia Price Performance

Shares of NASDAQ:MTVA traded down $0.57 during midday trading on Friday, reaching $9.19. 12,616 shares of the company’s stock were exchanged, compared to its average volume of 103,252. The stock has a market cap of $20.23 million, a price-to-earnings ratio of -1.10 and a beta of 0.29. The firm’s 50 day simple moving average is $9.17 and its two-hundred day simple moving average is $8.67. MetaVia has a fifty-two week low of $6.05 and a fifty-two week high of $30.25.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.86) by $1.32. Equities research analysts predict that MetaVia will post -3.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MTVA has been the subject of several recent research reports. HC Wainwright assumed coverage on MetaVia in a report on Thursday, September 4th. They issued a “buy” rating and a $132.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $82.50.

Hedge Funds Weigh In On MetaVia

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC grew its holdings in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,386 shares of the company’s stock after purchasing an additional 18,506 shares during the period. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.